Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care (2004)

Peer-Reviewed Study · Tier 1 — Primary Document · Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, Linde-Zwirble W · October 1, 2004

Williams MD et al., 2004-10-01: Analysis of 1999 hospital discharges in six states projected nationally. Severe sepsis was present in 4.9% of cancer hospitalisations, carried 37.8% in-hospital mortality, and was associated with 8.5% of all cancer deaths.

Overall, severe sepsis is associated with 8.5% (46,729) of all cancer deaths at a cost of 3.4 billion dollars per year.

Abstract (Results)

Williams MD et al., 2004-10-01: Analysis of 1999 hospital discharges in six states projected nationally. Severe sepsis was present in 4.9% of cancer hospitalisations, carried 37.8% in-hospital mortality, and was associated with 8.5% of all cancer deaths. CONFLICT OF INTEREST IS MATERIAL: all authors were at Lilly Research Laboratories, Eli Lilly & Company, maker of drotrecogin alfa (Xigris), the sepsis drug of that era; the study is a Lilly-authored database analysis. Comparator: cancer patients with severe sepsis vs other hospitalisations and vs the general population (RR 3.96 for severe sepsis hospitalisation). The 8.5% figure supports 'nearly 10 percent of cancer-related deaths' but applies to ALL cancer patients, not to chemotherapy recipients, and it is severe sepsis, not infection generally.